RedHill Biopharma Ltd. (RDHL) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
RDHL Revenue Growth
Revenue Breakdown (FY 2024)
RDHL's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
RDHL Revenue Analysis (2013–2024)
As of May 8, 2026, RedHill Biopharma Ltd. (RDHL) generated trailing twelve-month (TTM) revenue of $9.5 million, reflecting explosive growth of +58.6% year-over-year. The most recent quarter (Q2 2025) recorded $2.0 million in revenue, up 0.0% sequentially.
Looking at the longer-term picture, RDHL's 5-year compound annual growth rate (CAGR) stands at +5.0%, indicating steady revenue expansion. The company achieved its highest annual revenue of $85.8 million in 2021.
Revenue diversification analysis shows RDHL's business is primarily driven by Movantik (100%). With over half of revenue concentrated in Movantik, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including IRWD (+13.8% YoY), SUPN (+16.3% YoY), and PTGX (-91.5% YoY), RDHL has outperformed the peer group in terms of revenue growth. Compare RDHL vs IRWD →
RDHL Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| RDHLCurrent | $10M | +58.6% | +5.0% | -181.7% | |
 IRWD | $296M | +13.8% | -5.3% | 40.1% | |
 SUPN | $719M | +16.3% | +6.7% | -5.1% | |
 PTGX | $46M | -91.5% | +10.0% | -343.6% |
RDHL Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $8.0M | +23.2% | $4.9M | 60.3% | $-14,613,000 | -181.7% |
| 2023 | $6.5M | -89.4% | $3.1M | 47.0% | $12.6M | 193.4% |
| 2022 | $61.8M | -27.9% | $28.5M | 46.1% | $-42,844,000 | -69.3% |
| 2021 | $85.8M | +33.2% | $36.4M | 42.4% | $-81,135,000 | -94.6% |
| 2020 | $64.4M | +923.0% | $27.5M | 42.7% | $-63,684,000 | -99.0% |
| 2019 | $6.3M | -24.7% | $4.0M | 64.1% | $-43,201,000 | -686.7% |
| 2018 | $8.4M | +108.6% | $5.5M | 66.1% | $-39,331,000 | -470.5% |
| 2017 | $4.0M | +3867.3% | $1.9M | 46.9% | $-51,972,000 | -1297.0% |
| 2016 | $101K | +3266.7% | $-30,442,000 | -30140.6% | $-30,543,000 | -30240.6% |
| 2015 | $3K | -100.0% | $-21,999,000 | -733300.0% | $-22,002,000 | -733400.0% |
See RDHL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RDHL Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RDHL vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonRDHL — Frequently Asked Questions
Quick answers to the most common questions about buying RDHL stock.
Is RDHL's revenue growth accelerating or slowing?
RDHL revenue is accelerating at +58.6% year-over-year, exceeding the 5-year CAGR of +5.0%. TTM revenue reached $10M. Growth momentum has increased versus prior periods.
What is RDHL's long-term revenue growth rate?
RedHill Biopharma Ltd.'s 5-year revenue CAGR of +5.0% reflects the sustained expansion pattern. Current YoY growth of +58.6% is above this long-term average.
How is RDHL's revenue distributed by segment?
RDHL reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.